Here's the thing about fast track status that can kill shorts. Fast track status can sometimes get a drug approved sooner than most would think, and sometimes unexpectedly at that. If phase 3 results are so one sided thatperifosine works with controllable side effects, then the FDA CANNOT keep this drug from those getting the placebo. Once (and if) this happens the drug can hit the market fairly rapidly. To withhold a drug that works from those in need IS ethically wrong (though the FDA has done this with some drugs), and would likely move the drug to market rapidly.
crazitjo good post. Besides the short interest we have posters bashing and pushing other stocks which probably ties in with the short interest. The Yahoo Finance graph tells the story today with volume at 1,447.632 shares.